Johnson & Johnson Stock Guide

Should you invest in the stock now?

May 19, 2024

Early Bird Prime for May 19, 2024

Pharma stocks have been unpopular over the past year, and Johnson & Johnson (NYSE: JNJ) has been leading the charge in this unpopularity contest. 

The stock is down 3.33% in 2024, even as the rest of the market grows.

The market gave Johnson & Johnson's financial results in mid-April the cold shoulder. Investors were not impressed, and the stock took a hit. 

But Johnson & Johnson has been on a comeback tour lately, climbing 7% like a determined mountain goat.

Last week, Johnson & Johnson decided to shake things up by buying dermatology-focused biotech Proteologix. The market reacted positively, sending the stock price up. 

And if that wasn't enough excitement, they also exited their spinoff Kenvue (NYSE: KVUE) with a stake sale.

So, with all this good news, you might wonder if now is the time to buy Johnson & Johnson stock. Is the stock the golden ticket to success or another mirage in the desert of investment opportunities? Well, here’s the answer:

Subscribe to Early Bird Prime to read the rest.

Become a paying subscriber of Early Bird Prime to get access to this post and other subscriber-only content.

Already a paying subscriber? Sign In.

A subscription gets you:

  • • Expert analysis on the best stocks.
  • • Stock price predictions based on machine learning.
  • • Investing picks and recommendations.
  • • Advertisement-free.